Drug molecules with limited micromeritic properties &
aqueous solubility (about 90% of new API's having low solubility
in water) [1] are becoming increasingly prevalent in the
research and development of new drugs [2]. Nowadays,
increasing energy prices and the inefficient manufacturing
have made pharmaceutical companies face cost pressures.
Therefore, the primary aim of pharmaceutical material engineering
is to improve designed particles of solid pharmaceutical
dosage forms which results in improving the efficiency of
the manufacturing processes and giving a high degree of
functionality to the drug or excipient particles (especially of
pharmaceutical materials for direct compression) [3] in
pharmaceutical products. Materials in the solid state
depending on the internal packing of their molecules can be
found in either crystalline, polymorphism or amorphous (or a
combination of both). It has been shown that they can be
packed in a defined order (crystalline), have no long-range
three dimensional (3-D) order (amorphous) have different
repeating packing arrangements (polymorphic crystals) or
have solvent included (solvates and hydrates). Each of these
changes in internal packing of a solid will give rise to changes
in bulk properties such as physiochemical, mechanical, etc.
[4]. For the crystal form, it is possible to change the external